To ensure achievement of set operational objectives and to ensure desired business growth. Our current business is unified, adopting the traditional sales & marketing management styles. Embedded in this structure are Pharmaceutical and Veterinary business arms structured into territorial markets for ease of management and control. The Nigerian market and ECOWAS markets are thus similarly structured into districts and regions where Neimeth’s products are distributed.
The Pharmaceuticals business distributes:-
1. Ethical Products – comprising of Neimeth branded ethical products including our flagship home grown product CIKLAVIT for the management of sickle cell disease. In addition products such as Normoretic, flexodene, Tiocosid, etc and new branded generics are part of the portfolio.
2. Consumer Product – comprising 15 major product groups divided into 39 presentations. High volume products like NCP, Pyrantrin, Obron – 6, Homtamin G and Pancemol are included as part of consumer products portfolio.
Neimeth is now poised to re-enter the lucrative Nigerian Animal Health business, which has very robust volume and profit potentials. We expect to regain a controlling market share in a few years. We have introduced our own brand of poultry and large animal range of anthelmintics, as well as production enhancing medicaments. We will also enter into strategic alliances in key disease areas that show great business potentials.
Neimeth is firmly on ground in the Anglophone West African Countries of Ghana, Sierra Leone, Liberia and the Gambia. Our key products like Ciklavit, Homtamin G, NCP have been registered there and are in rising demand.